You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Lixte terminates license agreement with Taipei Medical University
MI Mobile App
Independent Networks Gain Little Traction On Virtual Multichannel Services
Big Strategy Decisions Ahead For Viacom As It Moves Into The CBS Fold
Street Talk Episode 48 - Bank M&A, Investing Against An Inverted Yield Curve Overview
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.